Circulating microRNAs for the prediction of metastasis in breast cancer patients diagnosed with early stage disease

Breast

Volumn 24, Issue 4, 2015, Pages 364-369

  Inns, Joseph ^a   James, Victoria ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Biomarker; Breast cancer; Metastasis; MicroRNA; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CIRCULATING NUCLEIC ACID DERIVATIVE; MICRORNA; NUCLEIC ACID; SMALL UNTRANSLATED RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

BLOOD LEVEL; BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CIRCULATING TUMOR CELL; CLINICAL ASSESSMENT; DIAGNOSTIC TEST; DNA MICROARRAY; GENE EXPRESSION; HUMAN; METASTASIS; METASTASIS POTENTIAL; MICRORNA BLOOD LEVEL; MOLECULAR DIAGNOSIS; NON INVASIVE PROCEDURE; NONHUMAN; ONCOTYPE DX TEST; PREDICTION; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; BLOOD; BREAST TUMOR; EARLY CANCER DIAGNOSIS; FEMALE; GENETICS; PATHOLOGY;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MICRORNAS; NEOPLASM STAGING;

EID: 84930936731     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2015.04.001     Document Type: Review

References (73)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: A Cancer J Clin 2011, 61:69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA: A Cancer J Clin 2013, 2013(63):11-30.
3. Scully O.J., Bay B.H., Yip G., Yu Y. Breast cancer metastasis. Cancer Genomics Proteomics 2012, 9:311-320.
4. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. The Oncol 2005, 10(Suppl 3):20-29.
5. Weigelt B., Peterse J.L., van 't Veer L.J. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005, 5:591-602.
6. Edge S.B., Compton C.C. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17:1471-1474.
7. Eroles P., Bosch A., Perez-Fidalgo J.A., Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012, 38:698-707.
8. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thurlimann B., Senn H.J., et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Annals of oncology. Off J Eur Soc Med Oncol/ESMO 2011, 22:1736-1747.
9. Haybittle J.L., Blamey R.W., Elston C.W., Johnson J., Doyle P.J., Campbell F.C., et al. Aprognostic index in primary breast cancer. Br J cancer 1982, 45:361-366.
10. Blamey R.W., Ellis I.O., Pinder S.E., Lee A.H., Macmillan R.D., Morgan D.A., et al. Survival of invasive breast cancer according to the Nottingham prognostic index in cases diagnosed in 1990-1999. Eur J cancer 2007, 43:1548-1555.
11. Ellis I.O., Bell J., Todd J.M., Williams M., Dowle C., Robins A.R., et al. Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma. Br J Cancer 1987, 56:295-299.
12. Rakha E.A., Soria D., Green A.R., Lemetre C., Powe D.G., Nolan C.C., et al. Nottingham prognostic index plus (NPI+): a modern clinical decision making tool in breast cancer. Br J Cancer 2014, 110:1688-1697.
13. Cheng L., Swartz M.D., Zhao H., Kapadia A.S., Lai D., Rowan P.J., et al. Hazard of recurrence among women after primary breast cancer treatment-a 10-year follow-up using data from SEER-medicare. Cancer epidemiology, biomarkers & prevention. APubl Am Assoc Cancer Res Cosponsored by Am Soc Prev Oncol 2012, 21:800-809.
14. Demicheli R., Abbattista A., Miceli R., Valagussa P., Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 1996, 41:177-185.
15. Demicheli R., Biganzoli E., Ardoino I., Boracchi P., Coradini D., Greco M., et al. Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrence. Cancer Sci 2010, 101:826-830.
16. Thames H.D., Buchholz T.A., Smith C.D. Frequency of first metastatic events in breast cancer: implications for sequencing of systemic and local-regional treatment. JClin Oncol 1999, 17:2649.
17. Marchionni L., Wilson R.F., Marinopoulos S.S., Wolff A.C., Parmigiani G., Bass E.B., et al. Impact of gene expression profiling tests on breast cancer outcomes. Evid Report/Technology Assess 2007, 1-105.
18. Harvey J.D.S., Bright-Thomas R., Winstanley J., Bishop H. Breast disease management: a multidisciplinary manual 2014, Oxford University Press.
19. Husemann Y., Geigl J.B., Schubert F., Musiani P., Meyer M., Burghart E., et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13:58-68.
20. Riethdorf S., Fritsche H., Muller V., Rau T., Schindlbeck C., Rack B., et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the cellsearch system. Clinical cancer research. Off J Am Assoc Cancer Res 2007, 13:920-928.
21. Hayashi N., Yamauchi H. Role of circulating tumor cells and disseminated tumor cells in primary breast cancer. Breast cancer 2012, 19:110-117.
22. Yu M., Stott S., Toner M., Maheswaran S., Haber D.A. Circulating tumor cells: approaches to isolation and characterization. Jcell Biol 2011, 192:373-382.
23. Ignatiadis M., Xenidis N., Perraki M., Apostolaki S., Politaki E., Kafousi M., et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. Journal of clinical oncology. Off J Am Soc Clin Oncol 2007, 25:5194-5202.
24. Pachmann K., Camara O., Kavallaris A., Krauspe S., Malarski N., Gajda M., et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. Journal of clinical oncology. Off J Am Soc Clin Oncol 2008, 26:1208-1215.
25. Pierga J.Y., Bidard F.C., Mathiot C., Brain E., Delaloge S., Giachetti S., et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clinical cancer research. Off J Am Assoc Cancer Res 2008, 14:7004-7010.
26. Madhavan D., Zucknick M., Wallwiener M., Cuk K., Modugno C., Scharpff M., et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clinical cancer research. Off J Am Assoc Cancer Res 2012, 18:5972-5982.
27. Schwarzenbach H., Alix-Panabieres C., Muller I., Letang N., Vendrell J.P., Rebillard X., et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clinical cancer research. Off J Am Assoc Cancer Res 2009, 15:1032-1038.
28. Diehl F., Li M., Dressman D., He Y., Shen D., Szabo S., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005, 102:16368-16373.
29. Diehl F., Schmidt K., Choti M.A., Romans K., Goodman S., Li M., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008, 14:985-990.
30. Silva J.M., Garcia J.M., Dominguez G., Silva J., Miralles C., Cantos B., et al. Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. Ann Surg Oncol 2002, 9:71-76.
31. Dawson S.J., Tsui D.W., Murtaza M., Biggs H., Rueda O.M., Chin S.F., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. NEngl J Med 2013, 368:1199-1209.
32. Cocucci E., Racchetti G., Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol 2009, 19:43-51.
33. Orozco A.F., Lewis D.E. Flow cytometric analysis of circulating microparticles in plasma. cytometry part A. JInt Soc Anal Cytol 2010, 77:502-514.
34. Garcia V., Garcia J.M., Pena C., Silva J., Dominguez G., Lorenzo Y., et al. Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett 2008, 263:312-320.
35. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
36. Han J., Lee Y., Yeom K.H., Kim Y.K., Jin H., Kim V.N. The drosha-DGCR8 complex in primary microRNA processing. Genes Dev 2004, 18:3016-3027.
37. Valencia-Sanchez M.A., Liu J., Hannon G.J., Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006, 20:515-524.
38. Liu H. MicroRNAs in breast cancer initiation and progression. Cellular and molecular life sciences. CMLS 2012, 69:3587-3599.
39. Chen W., Cai F., Zhang B., Barekati Z., Zhong X.Y. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour biology. JInt Soc Oncodevelopmental Biol Med 2013, 34:455-462.
40. Ma L., Reinhardt F., Pan E., Soutschek J., Bhat B., Marcusson E.G., et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010, 28:341-347.
41. Mattie M.D., Benz C.C., Bowers J., Sensinger K., Wong L., Scott G.K., et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006, 5:24.
42. van Schooneveld E., Wouters M.C., Van der Auwera I., Peeters D.J., Wildiers H., Van Dam P.A., et al. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast cancer research. BCR 2012, 14. R34.
43. Wang B., Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. JCancer Res Clin Oncol 2012, 138:1659-1666.
44. Wang H., Tan G., Dong L., Cheng L., Li K., Wang Z., et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PloS One 2012, 7. e34210.
45. Zhao F.-L., Hu G.-D., Wang X.-F., Zhang X.-H., Zhang Y.-K., Yu Z.-S. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer. JInt Med Res 2012, 40:859-866.
46. Roth C., Rack B., Müller V., Janni W., Pantel K., Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast cancer research. BCR 2010, 12. R90.
47. Ahmad A., Sethi S., Chen W., Ali-Fehmi R., Mittal S., Sarkar F.H. Up-regulation of microRNA-10b is associated with the development of breast cancer brain metastasis. Am J Transl Res 2014, 6:384-390.
48. Schwarzenbach H., Milde-Langosch K., Steinbach B., Müller V., Pantel K. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat 2012, 134:933-941.
49. Jung E.J., Santarpia L., Kim J., Esteva F.J., Moretti E., Buzdar A.U., et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012, 118:2603-2614.
50. Le M.T., Hamar P., Guo C., Basar E., Perdigao-Henriques R., Balaj L., et al. miR-200-containing extracellular vesicles promote breast cancer cell metastasis. JClin Investig 2014, 124:5109-5128.
51. Wu X., Somlo G., Yu Y., Palomares M.R., Li A.X., Zhou W., et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. JTransl Med 2012, 10:42.
52. Dawson S.J., Provenzano E., Caldas C. Triple negative breast cancers: clinical and prognostic implications. European J Cancer 2009, 45(Suppl 1):27-40.
53. Kleivi Sahlberg K., Bottai G., Naume B., Burwinkel B., Calin G.A., Borresen-Dale A.L., et al. Aserum MicroRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clinical cancer research. Off J Am Assoc Cancer Res 2015, 21:1207-1214.
54. Leivonen S.K., Makela R., Ostling P., Kohonen P., Haapa-Paananen S., Kleivi K., et al. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene 2009, 28:3926-3936.
55. Martello G., Rosato A., Ferrari F., Manfrin A., Cordenonsi M., Dupont S., et al. AmicroRNA targeting dicer for metastasis control. Cell 2010, 141:1195-1207.
56. Volinia S., Croce C.M. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci U S A 2013, 110:7413-7417.
57. Yoshimoto N., Toyama T., Takahashi S., Sugiura H., Endo Y., Iwasa M., et al. Distinct expressions of microRNAs that directly target estrogen receptor alpha in human breast cancer. Breast Cancer Res Treat 2011, 130:331-339.
58. Huang Q., Gumireddy K., Schrier M., le Sage C., Nagel R., Nair S., et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008, 10:202-210.
59. Rask L., Balslev E., Sokilde R., Hogdall E., Flyger H., Eriksen J., et al. Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. Cell Oncol 2014, 37:215-227.
60. Shen S., Sun Q., Liang Z., Cui X., Ren X., Chen H., et al. Aprognostic model of triple-negative breast cancer based on miR-27b-3p and node status. PloS One 2014, 9. e100664.
61. Smeets A., Daemen A., Vanden Bempt I., Gevaert O., Claes B., Wildiers H., et al. Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs. Breast Cancer Res Treat 2011, 129:767-776.
62. Song S.J., Poliseno L., Song M.S., Ala U., Webster K., Ng C., et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 2013, 154:311-324.
63. Tavazoie S.F., Alarcon C., Oskarsson T., Padua D., Wang Q., Bos P.D., et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-152.
64. Yan L.X., Huang X.F., Shao Q., Huang M.Y., Deng L., Wu Q.L., et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14:2348-2360.
65. Esteva F.J., Sahin A.A., Cristofanilli M., Coombes K., Lee S.J., Baker J., et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clinical cancer research. Off J Am Assoc Cancer Res 2005, 11:3315-3319.
66. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. Amultigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. NEngl J Med 2004, 351:2817-2826.
67. Leidner R.S., Li L., Thompson C.L. Dampening enthusiasm for circulating microRNA in breast cancer. PloS One 2013, 8. e57841.
68. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011, 108:5003-5008.
69. Meyer S.U., Kaiser S., Wagner C., Thirion C., Pfaffl M.W. Profound effect of profiling platform and normalization strategy on detection of differentially expressed microRNAs-a comparative study. PloS One 2012, 7. e38946.
70. Wang K., Yuan Y., Cho J.H., McClarty S., Baxter D., Galas D.J. Comparing the MicroRNA spectrum between serum and plasma. PloS One 2012, 7. e41561.
71. Meyer S.U., Pfaffl M.W., Ulbrich S.E. Normalization strategies for microRNA profiling experiments: a 'normal' way to a hidden layer of complexity?. Biotechnol Lett 2010, 32:1777-1788.
72. Dai X., Chen A., Bai Z. Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. Sci Reports 2014, 4:6566.
73. Peinado H., Aleckovic M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012, 18:883-891.